

Serial No. 09/868,974

Amendments to the Claims**1-26. (Cancelled)**

27. (cancelled).

28. (cancelled).

29. (cancelled).

30. (cancelled).

31. (cancelled).

32. (cancelled).

33. (cancelled).

34. (amended) A shelf-stable solution formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) molecule, wherein the molecule comprises the same amino acid sequence as a molecule selected from the group consisting of GLP-1(7-34), GLP-1(7-35), GLP-1(7-36), GLP-1(7-37), or the amide forms thereof, comprising and at least one modification selected from the group consisting of:

- (a) substitution of a glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, arginine, or D-lysine for lysine at position 26 and/or position 34 or substitution of a glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, lysine, or a D-arginine for arginine at position 36;
- (b) substitution of an oxidation-resistant amino acid for tryptophan at position 31;
- (c) substitution of at least one of: tyrosine for valine at position 16; lysine for serine at position 18; aspartic acid for glutamic acid at position 21; serine for glycine at position 22; arginine for glutamine at position 23; arginine for alanine at position 24; and glutamine for lysine at position 26; and
- (d) substitution comprising at least one of: glycine, serine, or cysteine for

Serial No. 09/868,974

alanine at position 8; aspartic acid, glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, or phenylalanine for glutamic acid at position 9; serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, or phenylalanine for glycine at position 10; and glutamic acid for aspartic acid at position 15;

a pharmaceutically acceptable preservative; and a tonicity modifier, wherein said formulation has a pH that is about 8.2 to about 8.8.

35. (cancelled)
36. (amended) The formulation of claim 34, wherein ~~the GLP-1 molecule is selected from the group consisting of GLP 1(7-34), GLP 1(7-35), GLP 1(7-36), GLP 1(7-37), or the amide forms thereof, and provided that arginine is substituted for lysine at position 34.~~
37. (previously presented) The formulation of claim 34 wherein the formulation is buffered by TRIS.
38. (cancelled)
39. (cancelled)
40. (previously presented) A method for treating diabetes comprising administering to a patient in need of such treatment an effective amount of the formulation of claim 34.
41. (previously presented) A shelf-stable solution formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) molecule which comprises the amino acid sequence:

R_1 -X-Glu-Gly¹⁰-Thr-Phe-Thr-Ser-Asp¹⁵-Val-Ser-Ser-Tyr-Leu²⁰-Y-Gly-Gln-Ala-Ala²⁵-Lys-Z-Phe-Ile-Ala³⁰-Trp-Leu-Val-Lys-Gly³⁵-Arg-R₂ (SEQ ID NO:2)

wherein R₁ is His or desamino-histidine, X is Ala, Gly or Val, Y is Glu or Gln, Z is Glu or Gln and R₂ is Gly-OH;

a pharmaceutically acceptable preservative; and a tonicity modifier,

Serial No. 09/868,974

wherein said formulation has a pH that is about 8.2 to about 8.8.

42. (cancelled)
43. (previously presented) The formulation of claim 41, wherein R₁ is L-histidine, X is Val, Y is Glu, Z is Glu, and R₂ is Gly-OH.
44. (previously presented) The formulation of claim 41 wherein the formulation is buffered by TRIS.
45. (cancelled)
46. (cancelled)
47. (previously presented) A method for treating diabetes comprising administering to a patient in need of such treatment an effective amount of the formulation of claim 41.